CONCENTRATION OF PSA AND PAP IN PROSTATIC CANCER
PATIENTS BEFORE AND 7 DAYS AFTER ORCHIDECTOMY
Article published in Urologia Polska 1997/50/3.
authors
-
Jan Kulpa 1, Ewa Wójcik 1, Jan Latała 2, Zygmunt Dobrowolski 3, Andrzej Stelmach 1
- Zakład Analityki i Biochemii Klinicznej Centrum Onkologii, Oddział w Krakowie
Dyrektor Centrum: prof. dr hab. med. Jan Skołyszewski
Kierownik Zakładu: dr n. chem. Jan Kulpa
1 Klinika Chirurgii Onkologicznej, Centrum Onkologii, Oddział w Krakowie
Kierownik Kliniki: doc. dr hab. med. Leszek Kołodziejski
2 Oddział Urologii, Woj. Szpital Zespol, im. G. Narutowicza w Krakowie
Ordynator Oddziału: dr med. Marek Gałka
3 Klinika Urologii Collegium Medicum UJ w Krakowie
p. o. Kierownik Kliniki: doc. dr hab. med. Zygmunt Dobrowolski
keywords
-
prostate prostatic cancer orchidectomy PSA, PAP hormonal status
summary
- Material and methods. The serum concentration of PSA, PAP, total
- testosterone, SHBG, albumin, LH, FSH and prolactin were determined in 20
- patients with prostate cancer before and 7 days after orchidectomy. Free
- testosterone level in serum was calculated for each patients basing on total
- testosterone, SHBG, and albumin concentrations.
- Results. Seven days after surgical castration when, compare to preoperative
- values, significant decrease of free testosterone (p<0.0001), PSA (p<0.001) and
- albumin (p<0.003) concentrations were found, while LH and FSH levels
- p<0.008 and p<0.0004 respctively
- of SHBG, prolactin, and PAP didn't demonstrate significant changes compared
- to preoperative level. At 7th day after operation significant positive correlation
- in prolactin vs. free testosterone level (p<0.002) and prolactin vs. PSA
- concentration (p<0.01) were observed. It might point to on important role of
- testosterone, produced in the periphery from adrenal substrates in controling
- cellular growth and function of prostate gland after castration.
- Conclusions. The observed decrease of PSA concentrations reflected changes
- in hormonal status. The results of PAP level may be a more adequate index of
- neoplastic process at that period of time.
references
- [1] Adlercreutz, H., Ranniko, S., Kairento, A. L., Karonen, S. L.: Hormonal
- pattern in prostatic cancer. II. Correlation with primary response to endocrine
- treatment. Acta Endocrinol., 1981, 98, 634-640.
- [2] Bartsch, W., Horst, H. ]., Becker, H., Nehse, G.: Sex hormone binding
- globulin binding capacity, testosterone, 5 alpha-dihydrotestosterone, oestradiol and
- prolactin in plasma of patients with prostatic carcinoma under yarious types of
- hormonal treatment. Acta Endocrinol., 1977, 85, 650-664.
- [3] Bruchovsky, N., Lesser, B., van Doorm, E., Craven, S.: Hormonal effects
- on cell proliferation in rat prostate. Vitamin Horm., 1975, 33, 61-102.
- [4] Csapo, Z., Brand K., Walther, R., Fokas K.: Comparative experimental stu-
- dy of the serum prostate specific antigen and prostatic acid phosphatase in serially
- transplantable human prostatic carcinoma lines in nude mice. J. Urol., 1988,140,
- 1032-1038.
- [5] Davies, P., Eaton, C. L.: Regulation of prostate growth. J. Endocrinol., 1991,
- 131, 5-17.
- [6] Denis, L.: Prostate cancer. Primary hormonal treatment. Cancer, 1993, 71,1050-
- 1058.
- [7] Geller, 1.: Basis for hormonal management of advanced prostate cancer. Cancer,
- 1993, 71, 1039-1045.
- [8] Geller, }., Liu, ]., Albert, }., Fay, W., Berry, C. C, Weis, P.: Relationship
- between human prostatic epithelial cell synthesis and tissue dihydrotestosterone
- level. Clin. Endocrinol., 1987, 26, 155-161.
- [9] Ghanadian, R., Puah, C. M., O'Donoghue, E. P. N.: Serum testosterone
- and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 1979, 39,
- 696-699.
- [10] Grasso, M., Buonaquidi, A., Mondina, R., Borsellino, G., Lania C,
- Banfi, G., Rigatti, P.: Plasma sex hormone binding glubulin in patients with
- prostatic carcinoma. Cancer, 1990, 66, 354-357.
- [11] Habib, K. A., Lee, I. R., Stitch, S. R., Smith, P. H.: Androgen levels in the
- plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of
- the prostate. J. Endocrinol., 1976, 71, 99-107.
- [12] Hanash, K. A., Mostofi, K. F.: Androgen effect on prostate specific antigen
- secretion. J. Surg. Oncol., 1992, 49, 202-204.
- [13] Henttu, P., Liao, S., Vihko, P.: Androgens up-regulate the human Prostate-
- specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prosta-
- tic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 1992, 130,
- 766-772.
- [14] Levell, M. J., Rowe, E., Glasham, R. W., Pidcock, N. B., Siddall, J. K.:
- Free testosterone in carcinoma of the prostate. The Prostate, 1985, 7, 363-367.
- [15] Levell, M. }., Siddall, J. K., Rowe, E., Glasham, R. W., Robinson, M. R. G.,
- Pidcock, N. B.: Relationship of testosterone, sex hormone binding globulin, and
- calculated free testosterone to subse±uent clinical progress in patients with carci-
- noma of the treated with bilateral orchdectomy or estrogens. The Prostate, 1987,
- 1, 17-21.
- [16] Marczyńska, A., Kulpa, }., Wójcik, E., Leńko, ]., Bugajski, A.: Prostate
- cancer - serum testosterone, sex hormone binding globulins (SHBG) and testoste-
- rone free index (TFI). Archiv Urol., 1990, 31, 57-66.
- [17] McConnell, J. D.: Androgen ablation and blockade in the treatment of benign
- prostatic hyperplasia. Urol. Clin. North Am., 1990, 17, 661-670.
- [18] Oesterling, J. E., Andrews, P. E., Suman, V. }., Zincke, H., Myeres, R. P:
- Preoperative androgen deprwation therapy: Artificial lowering of serum prostate
- antigen without downstaging the tumor. J. Urol., 1993, 149, 779-782.
- [19] Rohl, H. F., Benke, H. P: Effect of orchidectomy on serum concentrations of
- testosterone and dihydrotestosterone in patients with prostatic cancer.
- Scand. J. Urol. Nephrol., 1992, 26, 11-14.
- [20] Weber, J. P, Oesterling, J. E., Peters, C. A., Partin, A. W., Chan, D. W.,
- Walsh, P. C: The influence of reversible androgen deprwation on serum prostate
- antigen levels in men with benign prostatic hyperplasia. J. Urol., 1989,141, 987-
- 992.
|